The ARB-type hypertension singular drug market has suffered from depression… Boryung is the only one grown

While the single drug market for domestic ARB-type hypertension treatments has been decreased, Boryung Pharm has kept its steady growth.

According to the Hana Daetoo Securities’s analysis result of the UBIST data, the Boryung Pharm’s ‘Kanarb’ recorded KRW 7.3 billion outpatient prescription expenses, which were increased by 7.2% compared to the same quarterof the year before.

Among other ARB-...